PARSHALL B LYNNE 4

What Happened Parshall B. Lynne, a director of Ionis Pharmaceuticals (IONS), sold 4,466 shares at a weighted-average price of $76.19 (proceeds $340,265) and 534 shares at a weighted-average price of $76.97 (proceeds $41,102) on April 15, 2026. Total disposition was 5,000 shares for approximately $381,367. These were sales (not purchases) executed under a pre-established trading plan.

Key Details

• Transaction date: April 15, 2026 (reported on Form 4 filed April 17, 2026) — appears timely.
• Lot 1: 4,466 shares; reported weighted-average $76.19; actual sale prices ranged $75.77–$76.70 (per footnote).
• Lot 2: 534 shares; reported weighted-average $76.97; actual sale prices ranged $76.85–$77.115 (per footnote).
• Footnote: Sales were made pursuant to a Rule 10b5-1 trading plan adopted May 6, 2025. The filer offers to provide a breakdown of trades by price within the reported ranges upon request.
• Shares owned after the transaction: not specified in the details provided.

Context Sales executed under a Rule 10b5-1 plan are generally pre-scheduled and are often routine liquidity events rather than real-time signals about the insider’s view of the company. For retail investors, purchases by insiders tend to be more informative about insider conviction; this filing documents a planned sale totaling about $381K.